Tafluprost Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Tafluprost Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
54
Registered trials
20
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Tafluprost can convert its Small molecule drug profile and PGF2α biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Tafluprost (query alias: tafluprost) |
|---|---|
| Modality / target | Small molecule drug; PGF2α; PGF2α agonists |
| Highest global status | Approved |
| Originator | Santen Pharmaceutical Co., Ltd., AGC, Inc. (Japan) |
| Active developers | Santen Pharmaceutical Co., Ltd., Santen SA, Thea Pharma Inc. |
The MCP disease footprint includes Glaucoma, Open-Angle, Glaucoma, Ocular Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2100045465 | Phase 4 | Recruiting | 12 | pupil distance |
| TCTR20210224008 | Phase 2/3 | Pending (Not yet recruiting) | 40 | Not disclosed |
| ChiCTR2500101796 | Early Phase 1 | Completed | 30 | the changes in OSDI score from baseline at week 12 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Effectiveness and Safety of Tafluprost for Chinese Patients with Primary Open Angle Glaucoma and Ocular Hypertension: A Post-marketing Phase IV Study
Phase 4; n=not disclosed; evaluation: Positive. Reported fields: IOP = 21.0 mmHg ; IOP = 22.4 mmHg ; IOP = 22.5 mmHg
Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study
Phase 4; n=20; evaluation: Positive. Reported fields: TBUT = TBUT using PT was numerically inferior to that using NPT ; TBUT = TBUT using PT was numerically inferior to that using NPT
24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy
Phase 4; n=43; evaluation: Positive. Reported fields: IOP: P-Value = < 0.05; IOP = 22.2 mmHg (SD, 3.9)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Tafluprost addresses Glaucoma, Open-Angle, Glaucoma, Ocular Hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| Akorn Announces Agreement to Sell its Branded Ophthalmic Products to Théa | Approved | Financial terms not disclosed | |
| 2018-11-30 | Meiji Seika Pharma to Launch Two Products from Santen Pharmaceutical Co., Ltd. in Indonesia | Approved | Financial terms not disclosed |
| 2009-04-15 | Santen and Merck & Co., Inc Sign Licensing Agreement for Tafluprost, Treatment for Glaucoma and Ocular Hypertension | Approved | US$600.0M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Tafluprost oxidative degradation impurity and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Method for synthesizing tafluprost”. The milestone feed surfaced a patent-application signal described as “Method for purifying tafluprost”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
